# South Korea Retinal Drugs Market

> South Korea Retinal Drugs Market Research Report By Distribution Channel (Hospital pharmacy, Retail pharmacy, Online Pharmacy) and By Indication (Macular degeneration, Diabetic eye disease, Others) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.3%
- **2024:** $ 154.14 Million
- **2025:** $ 163.85 Million
- **2035:** $ 301.9 Million
- **Key Players:** Regeneron Pharmaceuticals (US), Novartis (CH), Roche (CH), Bayer (DE), Pfizer (US), Santen Pharmaceutical (JP), Horizon Therapeutics (IE), Apellis Pharmaceuticals (US), Eyenovia (US)

**Report ID:** MRFR/Pharma/50216-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/south-korea-retinal-drugs-market-51974

---

## Market Summary

## **South Korea Retinal Drugs Market Overview**

As per MRFR analysis, the South Korea Retinal Drugs Market Size was estimated at 145.11 (USD Million) in 2023. The South Korea Retinal Drugs Market Industry is expected to grow from 154.25(USD Million) in 2024 to 347.82 (USD Million) by 2035. The South Korea Retinal Drugs Market CAGR (growth rate) is expected to be around 7.672% during the forecast period (2025 - 2035)

**Key South Korea Retinal Drugs Market Trends Highlighted**

The South Korea Retinal Drugs Market is experiencing significant changes driven by several key factors. One of the primary market drivers is the increasing prevalence of retinal diseases, including diabetic retinopathy and age-related macular degeneration, which has been recognized as a growing health concern by South Korean health authorities. The aging population in South Korea is further fueling this demand, as older adults are more susceptible to vision impairment and related diseases. 

Moreover, advancements in drug formulations and delivery methods are contributing to the market's revitalization, enabling more effective treatments with fewer side effects.There are numerous opportunities to be explored in this market, particularly with the rise of biopharmaceuticals. The South Korean government has implemented supportive regulations to boost the development and approval of innovative therapies, creating an environment conducive to research and development. Companies are also increasingly collaborating with local universities and research institutions to foster innovation in retinal drug development. 

These partnerships can lead to breakthroughs that improve patient outcomes and drive market growth. Recent trends show a notable shift toward personalized medicine in retinal therapeutics, emphasizing targeted treatments based on individual patient profiles.The growing focus on patient-centric care is also prompting pharmaceutical companies to engage more with healthcare providers to ensure their products meet the specific needs of patients. 

Digital health technologies, including telemedicine and mobile health applications, are being integrated into treatment plans, enhancing patient monitoring and adherence to therapy. The South Korean healthcare system's emphasis on technological integration is driving these modern trends, making the market dynamic and responsive to patient needs.

Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review**

**South Korea Retinal Drugs Market Drivers**

**Increasing Prevalence of Retinal Disorders**

The rising incidence of retinal conditions, such as diabetic retinopathy and age-related macular degeneration (AMD) is driving substantial expansion in the South Korea retinal drugs market. According to the Korean Statistical Information Service, the percentage of people 65 and older in South Korea is predicted to climb to 24.9% by 2030, a result of the country's ageing population. Retinal medication demand is being driven by groups like the Korean Ophthalmological Society, which are promoting better screening and treatment practices in response. 

The proactive approach taken by government agencies to finance ophthalmic research and the increased awareness of eye health issues support this expansion even more. According to a Korean National Health Insurance Service report, the number of instances with diabetic retinopathy has risen by almost 21% in the last five years, underscoring the critical need for efficient treatment alternatives on the market.

**Advancements in Research and Development**

The South Korea Retinal Drugs Market Industry benefits immensely from advancements in Research and Development (R&D). The South Korean government has been actively investing in R&D initiatives, directed towards the development of innovative therapeutic solutions for retinal diseases. According to the Ministry of Science and ICT, the country's investment in R&D reached approximately 5% of its GDP, prompting biopharmaceutical companies to accelerate their research efforts.

Companies like Novartis and Bayer have established R&D centers in South Korea focusing on retinal drugs, thus increasing the pipeline of new therapies. The introduction of novel biologics and gene therapies is expected to revolutionize treatment options and positively impact the market, giving rise to a competitive edge in the global landscape.

**Supportive Regulatory Framework**

A supportive regulatory framework in South Korea significantly enhances the growth of the South Korea Retinal Drugs Market Industry. The Ministry of Food and Drug Safety (MFDS) has streamlined the approval process for new drugs, leading to shorter time-to-market for innovative retinal therapies. The agency's initiatives, such as the Conditional Approval System introduced in 2020, allow for expedited access to critical treatments for patients with retinal disorders.

As a result, companies like HanAll Biopharma are actively pursuing the development and commercialization of retinal drugs. The positive collaboration between the pharmaceutical industry and government regulatory agencies has led to a more conducive environment for medical advancements, which in turn fuels market growth as more therapies gain approval and reach patients in need.

**South Korea Retinal Drugs Market Segment Insights**

**Retinal Drugs Market Distribution Channel Insights**

The Distribution Channel segment of the South Korea Retinal Drugs Market plays a crucial role in ensuring the availability and accessibility of retinal drugs to patients and healthcare providers. Hospital pharmacies are pivotal in this segment as they provide tailored medications directly to inpatients and outpatients, often managing complex prescriptions and therapies for retinal disorders. 

Their integration with healthcare facilities facilitates efficient prescription handling and patient monitoring, making them a vital source of therapeutic access.Retail pharmacies, on the other hand, serve as an essential point of access for patients requiring retinal drugs, providing a convenient option for individuals to obtain their prescriptions. 

They are often strategically located in urban areas, ensuring that patients can quickly access necessary medications. The rise of online pharmacies has transformed the retail landscape, offering an alternative that caters to a tech-savvy population seeking convenience and privacy in their pharmaceutical purchases. This channel is particularly important for patients who may face mobility challenges or wish to avoid in-person visits, highlighting its expanding role in the distribution of retinal drugs.

As the South Korean healthcare system continues to evolve, driven by technological advancements and a shift toward patient-centric care, each distribution channel adapts to meet the needs of varied patient demographics, thereby enhancing the overall efficacy of the South Korea Retinal Drugs Market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Retinal Drugs Market Indication Insights**

The South Korea Retinal Drugs Market is witnessing significant growth driven by various indications, with a focus on conditions such as Macular degeneration and Diabetic eye disease. Macular degeneration remains a critical indication as it is a leading cause of vision loss among the aging population in South Korea, emphasizing the need for effective treatment options. The increasing prevalence of Diabetic eye disease, attributed to the rising number of diabetes cases in the nation, is also a significant driver for the market. This condition commonly leads to complications affecting retinal health, making timely intervention vital.

Other indications are emerging, although they hold a smaller share of the market compared to the aforementioned conditions. The market landscape is influenced by ongoing Research and Development efforts, government initiatives to raise awareness of ocular health, and advancements in treatment modalities which address the diverse needs of patients. Overall, the South Korea Retinal Drugs Market segmentation highlights crucial areas where innovations can improve patient outcomes and potentially enhance quality of life for individuals facing these serious eye conditions.

**South Korea Retinal Drugs Market Key Players and Competitive Insights**

The South Korea Retinal Drugs Market has observed significant growth in recent years, driven by an increasing prevalence of retinal diseases, rising awareness about eye health, and advancements in pharmaceutical research and development. The competitive landscape of this market is characterized by numerous players engaged in the development and commercialization of innovative therapies targeting various retinal conditions such as age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. 

Companies are leveraging their research capabilities and forming strategic partnerships to enhance their product pipelines and expand their market presence. As the market evolves, competitive insights reveal the dynamics of innovation, market penetration strategies, and collaboration among key players striving to meet the growing demand for effective retinal treatments in South Korea.Hanmi Pharmaceutical holds a noteworthy position in the South Korean retinal drugs market, driven by its strong commitment to innovation and extensive research capabilities. The company's focus on developing high-quality treatments for ocular diseases positions it as a key player in this niche segment. 

Hanmi Pharmaceutical leverages its expertise in biopharmaceuticals to enhance therapeutic options for retinal conditions. Its robust pipeline of potential products showcases the commitment to addressing unmet medical needs in the field of ophthalmology. Furthermore, the company's established distribution networks and partnerships with healthcare professionals ensure effective delivery and accessibility of its retinal drugs to patients, boosting its competitive edge within the South Korean market.Hugel has established itself as a significant player in the South Korean retinal drugs market, focusing on the development of innovative products aimed at treating various retinal diseases. 

The company’s portfolio includes cutting-edge therapies that address critical needs in the ophthalmic domain, reflecting its dedication to advancing eye care. Hugel’s strengths lie in its comprehensive product development process and ability to bring advanced treatment options to market efficiently. The company has actively pursued strategic mergers and acquisitions to enhance its capabilities and expand its reach, solidifying its position in the competitive landscape. 

Additionally, Hugel's commitment to research and development allows it to stay ahead of market trends, ensuring that it can respond effectively to the evolving needs of patients and healthcare providers in South Korea. The combination of strong product offerings and an innovative approach contributes to Hugel's growing footprint in the retinal drugs sector.

**Key Companies in the South Korea Retinal Drugs Market Include**

**South Korea Retinal Drugs Market Industry Developments**

Recent developments in the South Korea Retinal Drugs Market indicate a dynamic landscape driven by competition among key players such as Hanmi Pharmaceutical, Hugel, and Regeneron Pharmaceuticals. In October 2023, Hanmi Pharmaceutical announced advancements in its retinal drug pipeline, focusing on innovative treatments for age-related macular degeneration, capitalizing on a growing demand for effective therapies. Hugel also revealed its plans to expand its portfolio, which includes novel retinal therapies aimed at improving patient outcomes. 

The market's growth is underscored by significant increases in valuation, as companies like Novartis and Bayer report enhanced market presence due to strategic partnerships within the region. In terms of mergers and acquisitions, Santen Pharmaceutical completed the acquisition of a regional competitor in September 2023, bolstering its position within the sector. Continuous advancements in Research and Development among these companies, along with favorable regulatory support from the South Korean government aimed at enhancing healthcare access, are fueling market momentum.

The South Korean retinal drugs market is projected to see enhanced investment and innovation, particularly as ocular diseases become more prevalent in the aging population.

**South Korea Retinal Drugs Market Segmentation Insights**

## Market Drivers

### Increasing Aging Population

The aging population in South Korea is a crucial driver for the retinal drugs market. As individuals age, the prevalence of age-related retinal diseases, such as age-related macular degeneration (AMD) and diabetic retinopathy, tends to rise. According to recent statistics, approximately 15% of the population aged 65 and older is affected by some form of retinal disease. This demographic shift is expected to lead to a growing demand for effective retinal treatments, thereby expanding the market. The retinal drugs market is likely to experience significant growth as healthcare providers focus on developing innovative therapies tailored to this aging demographic. Furthermore, the increasing life expectancy in South Korea suggests that the number of individuals requiring retinal care will continue to rise, further propelling the market forward.

### Rising Healthcare Expenditure

In South Korea, increasing healthcare expenditure is a significant driver for the retinal drugs market. The government has been investing heavily in healthcare infrastructure and services, which has led to improved access to advanced medical treatments. In 2025, healthcare spending is projected to reach approximately 9.5% of the GDP, reflecting a commitment to enhancing patient care. This increase in funding allows for the development and distribution of innovative retinal drugs, making them more accessible to patients. The retinal drugs market stands to gain from this trend, as higher healthcare budgets facilitate research and development efforts, ultimately leading to the introduction of new therapies. As the population becomes more aware of available treatments, the demand for retinal drugs is expected to rise, further contributing to market expansion.

### Growing Awareness of Eye Health

The rising awareness of eye health among the South Korean population is a notable driver for the retinal drugs market. Public health campaigns and educational initiatives have been instrumental in informing individuals about the importance of regular eye examinations and early detection of retinal diseases. This heightened awareness is likely to lead to an increase in patient consultations and subsequent demand for retinal treatments. The retinal drugs market is expected to benefit from this trend, as more individuals seek medical advice and treatment options for their eye health concerns. Furthermore, as awareness continues to grow, it may encourage further research and development in the field, leading to the introduction of new and effective therapies for retinal diseases.

### Supportive Regulatory Environment

The regulatory environment in South Korea plays a pivotal role in shaping the retinal drugs market. The government has established frameworks that facilitate the approval and commercialization of new retinal therapies. Regulatory bodies are increasingly prioritizing the review of innovative treatments, which can expedite their entry into the market. This supportive stance is likely to encourage pharmaceutical companies to invest in research and development for retinal drugs. The retinal drugs market is expected to thrive as a result of this conducive regulatory landscape, which not only fosters innovation but also ensures that patients have timely access to new therapies. As regulations continue to evolve, they may further enhance the market's growth potential.

### Advancements in Medical Technology

Technological innovations in the field of ophthalmology are significantly influencing the retinal drugs market. The introduction of novel drug delivery systems, such as sustained-release implants and targeted therapies, enhances the efficacy of treatments for retinal diseases. For instance, recent advancements have led to the development of biologics that can be administered less frequently while maintaining therapeutic effectiveness. This shift towards more efficient treatment options is likely to attract both healthcare providers and patients, thereby stimulating market growth. The retinal drugs market is poised to benefit from these advancements, as they not only improve patient outcomes but also reduce the overall burden on healthcare systems. As technology continues to evolve, the potential for new therapeutic modalities will likely expand, further driving the market.

## Future Outlook

The [Retinal Drugs Market](https://www.marketresearchfuture.com/reports/retinal-drugs-market-11735) is projected to grow at a 6.3% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence of retinal diseases, and rising healthcare expenditure.

**New opportunities:**

- Development of personalized medicine solutions for retinal disorders.
- Expansion of telemedicine platforms for remote patient monitoring.
- Investment in AI-driven diagnostic tools for early detection of retinal diseases.

By 2035, the retinal drugs market is expected to achieve substantial growth, driven by innovation and strategic investments.

## Segment Insights

### By Distribution Channel: Hospital Pharmacy (Largest) vs. Online Pharmacy (Fastest-Growing)

In the South Korea retinal drugs market, the distribution channel landscape is primarily dominated by Hospital Pharmacy, which holds the largest share due to its established infrastructure and consistent demand from healthcare providers. Retail Pharmacy also plays a significant role, offering accessibility to patients, but it trails behind in overall market presence. Online Pharmacy, while currently smaller in share, is gaining traction as e-commerce adoption increases and convenience becomes a key factor for consumers.

The growth trends in the distribution channels highlight a shift towards digital platforms, particularly with Online Pharmacy emerging as the fastest-growing segment. Factors such as increased smartphone penetration and a growing trend towards telemedicine are driving this change. Meanwhile, Hospital Pharmacy remains strong due to its direct relationships with hospitals and clinics, providing a steady flow of prescriptions and ensuring efficient patient care.

Hospital Pharmacy (Dominant) vs. Online Pharmacy (Emerging)

Hospital Pharmacy serves as the dominant distribution channel in the South Korea retinal drugs market, benefiting from strong ties with medical institutions and a reputation for reliability in dispensing medications. Its well-established presence is complemented by an extensive network that facilitates the distribution of specialty drugs. In contrast, Online Pharmacy is emerging rapidly, appealing particularly to tech-savvy consumers who prefer the convenience of ordering medications from home. This segment utilizes advancements in technology to enhance user experience and streamline operations, including home delivery services, making it increasingly attractive to a range of patients.

### By Indication: Macular Degeneration (Largest) vs. Diabetic Eye Disease (Fastest-Growing)

In the South Korea retinal drugs market, the distribution of market share among segment values showcases that macular degeneration holds the largest share, positioning itself as the primary focus for pharmaceutical developments. Diabetic eye disease, while smaller in current market share compared to macular degeneration, is trending upward due to rising diabetes prevalence, highlighting enhanced awareness and diagnosis. 

Growth trends in this market segment are driven by the increasing incidence of age-related eye conditions and advancements in drug formulations. The demand for effective treatment options is creating an accelerated market for diabetic eye disease therapies, reflecting its status as the fastest-growing segment. This growth is supported by ongoing research and development efforts aimed at improving patient outcomes and increasing treatment accessibility.

Macular Degeneration (Dominant) vs. Diabetic Eye Disease (Emerging)

Macular degeneration is characterized by its significant market presence and is predominantly driven by an aging population and the prevalence of this age-related condition. Its dominance in the South Korea retinal drugs market is emphasized by continuous advancements in therapy options, including injections and innovative drug formulations. Conversely, diabetic eye disease is recognized as an emerging segment with great potential. The rise in incidences of diabetes, coupled with increased screening and awareness, has positioned it as a key area for growth. Emerging treatments and patient education initiatives are propelling this segment forward, making it a focal point for both existing and new players in the market.

## Competitive Benchmarking

The retinal drugs market in South Korea is characterized by a dynamic competitive landscape, driven by increasing prevalence of retinal diseases and a growing aging population. Key players such as Regeneron Pharmaceuticals (US), Novartis (CH), and Bayer (DE) are strategically positioned to leverage innovation and partnerships to enhance their market presence. Regeneron Pharmaceuticals (US) focuses on the development of novel therapies, particularly in the area of age-related macular degeneration (AMD), while Novartis (CH) emphasizes its commitment to research and development, aiming to expand its portfolio through strategic acquisitions. Bayer (DE) is also actively pursuing collaborations to enhance its product offerings, indicating a collective trend towards innovation and strategic partnerships among these companies.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for a diverse range of products and services, but also intensifies competition as companies vie for market share.

In October  Regeneron Pharmaceuticals (US) announced a collaboration with a local biotech firm to accelerate the development of a new retinal drug targeting diabetic retinopathy. This partnership is significant as it not only enhances Regeneron’s R&D capabilities but also allows for localized insights into the South Korean market, potentially leading to more tailored treatment options. Similarly, in September 2025, Novartis (CH) launched a new digital platform aimed at improving patient engagement and adherence to retinal therapies. This initiative underscores the growing importance of digital health solutions in enhancing treatment outcomes and patient satisfaction.Moreover, in August 2025, Bayer (DE) expanded its existing product line by introducing a new formulation of its retinal drug, which is designed to improve patient compliance through less frequent dosing. This strategic move reflects Bayer’s commitment to addressing patient needs and enhancing the overall treatment experience, which is crucial in a competitive market.

As of November  current trends in the retinal drugs market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in drug development and patient management. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex regulatory environments and accelerating innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and supply chain reliability. This shift may ultimately reshape the market dynamics, fostering a landscape where companies that prioritize R&D and patient-centric solutions will thrive.

## Recent News & Developments

Recent developments in the South Korea Retinal Drugs Market indicate a dynamic landscape driven by competition among key players such as Hanmi Pharmaceutical, Hugel, and Regeneron Pharmaceuticals. In October 2023, Hanmi Pharmaceutical announced advancements in its retinal drug pipeline, focusing on innovative treatments for age-related macular degeneration, capitalizing on a growing demand for effective therapies. Hugel also revealed its plans to expand its portfolio, which includes novel retinal therapies aimed at improving patient outcomes. 

The market's growth is underscored by significant increases in valuation, as companies like Novartis and Bayer report enhanced market presence due to strategic partnerships within the region. In terms of mergers and acquisitions, Santen Pharmaceutical completed the acquisition of a regional competitor in September 2023, bolstering its position within the sector. Continuous advancements in Research and Development among these companies, along with favorable regulatory support from the South Korean government aimed at enhancing healthcare access, are fueling market momentum.

The South Korean retinal drugs market is projected to see enhanced investment and innovation, particularly as ocular diseases become more prevalent in the aging population.

## Report Scope

| MARKET SIZE 2024 | 154.14(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 163.85(USD Million) |
| MARKET SIZE 2035 | 301.9(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.3% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Regeneron Pharmaceuticals (US), Novartis (CH), Roche (CH), Bayer (DE), Pfizer (US), Santen Pharmaceutical (JP), Horizon Therapeutics (IE), Apellis Pharmaceuticals (US), Eyenovia (US) |
| Segments Covered | Distribution Channel, Indication |
| Key Market Opportunities | Advancements in gene therapy and personalized medicine enhance prospects in the retinal drugs market. |
| Key Market Dynamics | Rising demand for innovative retinal therapies drives competition and regulatory scrutiny in South Korea's retinal drugs market. |
| Countries Covered | South Korea |

## Frequently Asked Questions

**Q: What was the market valuation of the South Korea retinal drugs market in 2024?**
A: The market valuation was $154.14 Million in 2024.

**Q: What is the projected market valuation for the South Korea retinal drugs market by 2035?**
A: The projected valuation for 2035 is $301.9 Million.

**Q: What is the expected CAGR for the South Korea retinal drugs market during the forecast period 2025 - 2035?**
A: The expected CAGR is 6.3% during the forecast period 2025 - 2035.

**Q: Which distribution channel had the highest valuation in the South Korea retinal drugs market in 2024?**
A: Retail Pharmacy had the highest valuation at $120.0 Million in 2024.

**Q: What was the valuation for the Online Pharmacy segment in the South Korea retinal drugs market in 2024?**
A: The Online Pharmacy segment was valued at $54.14 Million in 2024.

**Q: Which indication segment is projected to grow the most in the South Korea retinal drugs market by 2035?**
A: Diabetic Eye Disease is projected to grow the most, with a valuation of $140.0 Million in 2024.

**Q: Who are the key players in the South Korea retinal drugs market?**
A: Key players include Regeneron Pharmaceuticals, Novartis, Roche, Bayer, Pfizer, Santen Pharmaceutical, Horizon Therapeutics, Apellis Pharmaceuticals, and Eyenovia.

**Q: What was the valuation for the Macular Degeneration segment in the South Korea retinal drugs market in 2024?**
A: The Macular Degeneration segment was valued at $60.0 Million in 2024.

**Q: How does the valuation of the Others segment compare to other indications in 2024?**
A: The Others segment was valued at $24.14 Million, which is lower than both Macular Degeneration and Diabetic Eye Disease.

**Q: What is the significance of the South Korea retinal drugs market's growth potential?**
A: The market's growth potential is indicated by the projected increase to $301.9 Million by 2035, reflecting a robust demand for retinal therapies.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-retinal-drugs-market-51974*